Exploring new perspectives to make extraordinary discoveries

At Montara, we’re developing safer, more efficacious therapies to improve the lives of patients with neurological diseases.

Our mission is to develop innovative therapies for diseases of the brain by leveraging our proprietary platform to enhance safety and efficacy to enable pharmacological drugging of established targets.

Introducing BrainOnly™, the uniquely versatile platform designed to prevent peripheral toxicities and concentrate neurological drugs’ activity in the brain, enhancing safety, increasing therapeutic index, and improving efficacy

Many promising drug candidates for neurological diseases fail to advance due to dose-limiting, off-tissue peripheral toxicities, which impede both safety and efficacy.

BrainOnly is a breakthrough platform that aims to prevent peripheral adverse events associated with neuroscience drugs. It enables brain-selective pharmacology by leveraging both existing and novel Brain-Targeting Chimeras (BrainTAC^™) while restricting deleterious on-target/off-tissue peripheral activity. It holds the potential to deliver a new generation of brain-targeted therapeutics.

	Access many currently undruggable targets and enhance the profile of existing drugs
	Utilize with novel or existing small molecule inhibitors or activators
	Broad applicability across neurodegenerative and neurological diseases and brain cancer

Learn more about our science

Solid experience with a fresh perspective

We are Montara Therapeutics, a precision medicine neuroscience biotech startup based in San Francisco. Our experienced team has founded successful biotech companies, and we are supported by world-class scientific and chemistry advisory boards.

We present a new approach to tackling challenging established targets, along with unique experience in developing enzyme activators and domain expertise in mitophagy.

Learn more about our team